Vascular endothelial growth factor polymorphisms -1154 G/A and -460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer

DNA and Cell Biology

Volumn 27, Issue 10, 2008, Pages 569-574

  Cacev, Tamara ^a   Loncar, Bozo ^b   Seiwerth, Sven ^c   Spaventi, Sime ^d   Kapitanovic, Sanja ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b University of Zagreb   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d CROATIAN ACADEMY OF SCIENCES AND ARTS   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

5' UNTRANSLATED REGIONS; AGED; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 52749085694     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2008.0756     Document Type: Article

References (28)

1. Balasubramanian, S.P., Cox, A., Cross, S.S., Higham, S.E., Brown, N.J., and Reed, M.W. (2007). Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer 121, 1009-1016.
2. Cacev, T., Radosevic, S., Spaventi, R., Pavelic, K., and Kapitanovic, S. (2005). NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer. Gut 54, 1129-1135.
3. Chae, Y.S., Kim, J.G., Shon, S.K., Cho, Y.Y., Moon, J.H., Bae, H.I., Park, J.Y., Lee, M.H., Lee, H.C., Chung, H.Y., and Yu, W. (2006). Investigation of VEGF polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology 71, 266-272.
4. Cilley, J.C., Barfi, K., Benson, A.B., and Mulcahy, M.F. (2007). Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 7, 739-749.
5. Ellis, L.M., Takahashi, Y., Liu, W., and Shaheen, R.M. (2000). Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 5, 11-15.
6. Ferrara, N. (2004). VEGF: basic science and clinical progress. Endocrine Rev 25, 581-611.
7. Hoehe, M.R., Timmermann, B., and Lehrach, H. (2003). Human interindividual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics. Curr Pharm Biotechnol 4, 351-378.
8. Howell, W.M., Bateman, A.C., Turner, S.J., Collins, A., and Theaker, J.M. (2002). Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 4, 229-232.
9. Ishigami, S.I., Arii, S., Furutani, M., Niwano, M., Harada, T., Mizumoto, M., Mori, A., Onodera, H., and Imamura, M. (1998). Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 78, 1379-1384.
10. Jacobs, E.J., Feigelson, H.S., Bain, E.B., Brady, K.A., Rodriguez, C., Stevens, V.L., Patel, A.V., Thun, M.J., and Calle, E.E. (2006). Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8, R22.
11. Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J., Novotny, W.F., Lieberman, G., Griffing, S., and Bergsland, E. (2003). Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21, 60-65.
12. Kim, J.G., Shom, S.K., Chae, Y.S., Cho, Y.Y., Bae, H.I., Yan, G., Park, J.Y., Lee, M.H., Chung, H.Y., and Yi, W. (2007). Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol 18, 1030-1036.
13. Koukourakis, M.I., Papazoglou, D., Giatromanolaki, A., Bougioukas, G., Maltezos, E., and Sivridis, E. (2004). VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46, 293-298.
14. Lin, C.C., Wu, H.C., Tsai, F.J., Chen, H.Y., and Chen, W.C. (2003). Vascular endothelial growth factor gene -460 C/T polymorphism is a biomarker for prostate cancer. Urology 62, 374-377.
15. McCarron, S.L., Edwards, S., Evans, P.R., Gibbs, R., Dearnaley, D.P., Dowe, A., Southgate, C., Easton, D.C., Eeles, R.A., and Howell, W.M. (2002). Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62, 3369-3372.
16. Ogata, Y., Matono, K., Mizobe, T., Ishibashi, N., Mori, S., Akagi, Y., Ikeda, S., Ozasa, H., Murakami, H., and Shirouzu, K. (2006). The expression of vascular endothelial growth factor determines the efficacy of post-operative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Oncol Rep 15, 1111-1116.
17. Onen, I.H., Konac, E., Eroglu, M., Guneri, C., Biri, H., and Ekmekci, A. (2008). No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population. Mol Biol Rep 35, 17-22.
18. Ries, L.A.G., Melbert, D., Krapcho, M., Stinchcomb, D.G., Howlader, N., Horner, M.J., Mariotto, A., Miller, B.A., Feuer, E.J., Altekruse, S.F., Lewis, D.R., Clegg, L., Eisner, M.P., Reichman, M., and Edwards, B.K. (eds.). (2007). SEER Cancer Statistics Review, 1975-2005 (National Cancer Institute, Bethesda, MD). http://seer.cancer.gov/crs/1975_2005/.
19. Rmali, K.A., Puntis, M.C., and Jiang, W.G. (2007). Tumour-associated angiogenesis in human colorectal cancer. Colorectal Dis 9, 3-14.
20. Sfar, S., Hassen, E., Saad, H., Mosbah, F., and Chouchane, L. (2006). Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 35, 21-28.
21. Shahbazi, M., Fryer, A.A., Pravica, V., Brogan, I.J., Ramsay, H.M., Hutchinson, I.V., and Harden, P.N. (2002). VEGF gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13, 260-264.
22. Spaventi, R., Pecur, L., Pavelic, K., Pavelic, Z.P., Spaventi, S., and Stambrook, P.J. (1994). Human tumour bank in Croatia: a possible model for a small bank as a part of future European tumour bank network. Eur J Cancer 30A, 419.
23. Stevens, A., Soden, J., Brenchley, P.E., Ralph, S., and Ray, D.W. (2003). Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63, 812-816.
24. Takahashi, Y., Kitadai, Y., Bucana, C.D., Cleary, K.R., and Ellis, L.M. (1995). Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55, 3964-3968.
25. Takeda, A., Shimada, H., Imaseki, H., Okazumi, S., Natsume, T., Suzuki, T., and Ochiai, T. (2000). Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumour markers. Oncol Rep 7, 333-338.
26. Walsh, D.A. (2007). Pathophysiological mechanisms of angiogenesis. Adv Clin Chem 44, 187-221.
27. Watson, C.J., Webb, N.J., Bottomley, M.J., and Brenchley, P.E. (2000). Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12, 1232-1235.
28. Zhai, R., Liu, G., Zhou, W., Su, L., Heist, R.S., Lynch, T.J., Wain, J.C., Asomaning, K., Lin, X., and Christiani, D.C. (2008). Vascular endothelial growth factor genotypes, haplotypes, gender and the risk of non small cell lung cancer. Clin Canc Res 14, 612-617.